Rigel (RIGL) EVP uses 3,546 shares to cover stock tax liability
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Furey Raymond J.
Role
EVP, GC, CCO & Corp Sec
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 3,546 | $34.62 | $123K |
Holdings After Transaction:
Common Stock — 32,316 shares (Direct)
Footnotes (1)
FAQ
What insider transaction did RIGL executive Raymond J. Furey report?
Raymond J. Furey reported a tax-withholding disposition of 3,546 Rigel common shares on February 10, 2026. The Form 4 shows this was to cover obligations rather than an open-market buy or sell transaction.
What does transaction code F mean in the RIGL Form 4 filing?
Transaction code F indicates payment of exercise price or tax liability by delivering securities. In this case, 3,546 Rigel shares were used to satisfy tax obligations, rather than being sold in a traditional open-market trade.
What is Raymond J. Furey’s role at Rigel Pharmaceuticals (RIGL)?
Raymond J. Furey is listed as an officer of Rigel Pharmaceuticals with the title “EVP, GC, CCO & Corp Sec.” This means he serves as Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary.
Was the RIGL insider transaction a direct or indirect ownership change?
The filing shows the transaction as direct ownership (code D). This indicates the 3,546 shares used for tax withholding, and the remaining 32,316 shares, are held directly by Raymond J. Furey rather than through an intermediary entity.